Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL14774852 | 0.98 | CES2 (0.48) | CES2CES1KEAP1CYP2C19DAO | |
| Fluoride SCHEMBL14931714 | 0.98 | CES2 (0.48) | CES2CES1KEAP1CYP2C19DAO | |
| Fumaric Acid SCHEMBL28542597 | 0.90 | HCAR2 (0.50) | CES2CES1KEAP1CYP2C19DAO | |
| Pyridine SCHEMBL30437342 | 0.90 | TSHR (0.47) | CES2CES1KEAP1CYP2C19DAO | |
| Pyridine SCHEMBL29016896 | 0.89 | TSHR (0.46) | CES2CES1KEAP1CYP2C19DAO | |
| Pyridine SCHEMBL28404147 | 0.89 | TSHR (0.46) | CES2CES1KEAP1CYP2C19DAO | |
| SCHEMBL4619853 | 0.88 | POLB (0.50) | CES2CES1KEAP1CYP2C19DAO | |
| SCHEMBL1527335 | 0.83 | ALOX5 (0.47) | CES2CES1KEAP1CYP2C19DAO | |
| SCHEMBL891673 | 0.83 | ALOX5 (0.47) | CES2CES1KEAP1CYP2C19DAO | |
| SCHEMBL1527327 | 0.83 | ALOX5 (0.47) | CES2CES1KEAP1CYP2C19DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875159-A | Composite gel of modified hyaluronic acid, preparation method and application of composite gel in cosmetic filling | 广东瀚润生物科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-109627374-B | Polytetrafluoroethylene material with low linear expansion coefficient and adhesive property and preparation method thereof | 上海嘉诺密封技术有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-112898835-A | Low-temperature-resistant rubber cable coating and preparation method thereof | 广东金源宇电线电缆有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-109704626-B | Organic fluorine modified glycol amine substituted polycarboxylic acid cement grinding aid and preparation method thereof | 湖南辰砾新材料有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-108129620-B | Sulfonic acid type block copolymer aqueous dispersant of RAFT technology | 英德科迪颜料技术有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-108250900-B | Water-based epoxy graphene low-zinc antirust primer | 明光科迪新材料有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-108165069-B | High-content aqueous graphene dispersion liquid and preparation method thereof | 明光科迪新材料有限公司 | 2020-09-01 | — | — | CN | claimed |
| WO-2016162878-A1 | AN ADVANTAGEOUS PROCESS FOR PREPARING 1-AZONIABICYCLO[2.2.2]OCTANE,3-[(HYDROXYDI-2-THIENYLACETYL)OXY]-1-(3¬PHENOXYPROPYL)-, BROMIDE, (3R)- AND ITS NOVEL CRYSTALLINE FORM-I | HARMAN FINOCHEM LIMITED (IN) | 2016-10-13 | — | — | WO | claimed |
| EP-2552913-B1 | METHOD FOR SYNTHESIS OF TIOTROPIUM BROMIDE | BILGIC MAHMUT (TR) | 2016-08-03 | — | — | EP | claimed |
| US-9242979-B2 | Methods for the synthesis of tiotropium bromide | BILGIC MAHMUT (TR) | 2016-01-26 | — | — | US | claimed |
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2012-12-20 | — | — | US | claimed |
| WO-2011123080-A1 | METHOD FOR SYNTHESIS OF TIOTROPIUM BROMIDE | BILGIC MAHMUT (TR) | 2011-10-06 | — | — | WO | claimed |
| US-20080214600-A1 | Quaternized Quinuclidine Esters | ALMIRALL PRODESFARMA, SA (ES) | 2008-09-04 | — | — | US | claimed |
| EP-1725552-B1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | claimed |
| EP-1725552-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | Almirall Prodesfarma, S.A. (ES) | 2006-11-29 | — | — | EP | claimed |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2006-01-05 | — | — | US | claimed |
| WO-2005090342-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL PRODESFARMA, SA (ES) | 2005-09-29 | — | — | WO | claimed |
| EP-1471919-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | claimed |
| EP-1471919-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066063-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | NQO2, QPCT, QARS1 | CES2 1023/4885CES1 601/4885KEAP1 84/4885 |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | CYP17A1, HSD17B7, NR5A1 | CES2 1227/4885CES1 796/4885KEAP1 2128/4885 |
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | CYP17A1, HSD17B7, NR5A1 | CES2 1227/4885CES1 796/4885KEAP1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.